LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced Electron Microscopy Reveals Fine Structure of Active Signaling Complexes

By LabMedica International staff writers
Posted on 07 Jul 2014
Image: A structural model of the beta2 adrenergic receptor-arrestin signaling complex as deduced by electron microscopy, cross-linking, and mass spectrometry (Photo courtesy of Duke University).
Image: A structural model of the beta2 adrenergic receptor-arrestin signaling complex as deduced by electron microscopy, cross-linking, and mass spectrometry (Photo courtesy of Duke University).
A team of molecular biologists used advanced electron microscopy and mass spectroscopy techniques to determine the structure of the functional human beta2AR (beta2 adrenergic receptor)-beta-arrestin-1 signaling complex.

Members of arrestin/beta-arrestin protein family are thought to participate in agonist-mediated desensitization of G-protein-coupled receptors (GPCRs) and cause specific dampening of cellular responses to stimuli such as hormones, neurotransmitters, or sensory signals.

While a recent barrage of structural data on a number of GPCRs including the beta2AR–G-protein complex has provided novel insights into the structural basis of receptor activation, information has been lacking on the recruitment of beta-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor–beta-arrestin complexes for structural studies.

Investigators at Duke University (Durham, NC, USA) and colleagues at the University of Michigan (Ann Arbor, USA) and Stanford University (Palo Alto, CA, USA) devised a strategy for forming and purifying a functional human beta2AR–beta-arrestin-1 complex that allowed them to visualize its architecture by single-particle negative-stain electron microscopy and to characterize the interactions between beta2AR and beta-arrestin 1 using hydrogen–deuterium exchange mass spectrometry (HDX-MS) and chemical cross linking.

Electron microscopy two-dimensional averages and three-dimensional reconstructions revealed bimodal binding of beta-arrestin 1 to the beta2AR, involving two separate sets of interactions, one with the phosphorylated carboxyl terminus of the receptor and the other with its seven-transmembrane core. Areas of reduced HDX together with identification of cross linked residues suggested engagement of the finger loop of beta-arrestin 1 with the seven-transmembrane core of the receptor.

A molecular model of the beta2AR–beta-arrestin signaling complex was made by docking activated beta-arrestin and beta2AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and cross linking. This model, which was published in the June 22, 2014, edition of the journal Nature, provided valuable insights into the overall architecture of a receptor–arrestin complex.

“Arrestin’s primary role is to put the cap on GPCR signaling. Elucidating the structure of this complex is crucial for understanding how the receptors are desensitized in order to prevent aberrant signaling,” said co-senior author Dr. Georgios Skiniotis, professor of life sciences at the University of Michigan.

Related Links:

Duke University
University of Michigan
Stanford University


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more